更新于：2024-09-19

HIPK4

更新于：2024-09-19

基本信息

别名

FLJ32818、HIPK4、homeodomain interacting protein kinase 4

+ [1]

简介

Protein kinase that phosphorylates human TP53 at Ser-9, and thus induces TP53 repression of BIRC5 promoter (By similarity). May act as a corepressor of transcription factors (Potential).

关联

100 项与 HIPK4 相关的临床结果

登录后查看更多信息

100 项与 HIPK4 相关的转化医学

登录后查看更多信息

0 项与 HIPK4 相关的专利（医药）

登录后查看更多信息

项与 HIPK4 相关的文献（医药）

2022-09-01·Journal of Biological Chemistry

Homeodomain-interacting protein kinase HIPK4 regulates phosphorylation of manchette protein RIMBP3 during spermiogenesis

Article

作者: Liu, Xiaofei ; Wang, Cheng ; Guo, Xuejiang ; Chen, Yu ; Situ, Chenghao ; Jiang, Tao ; Meng, Ru ; Wu, Yifei ; Yang, Xiaoyu ; Guo, Yueshuai ; Zhang, Jun ; Hu, Zhibin ; Zang, Chunyan

Nonobstructive azoospermia (NOA) is the most serious form of spermatogenesis abnormalities in male infertility. Genetic factors are important to consider as elements leading to NOA. Although many pathogenic genes have been reported, the causative genes of NOA for many patients are still unknown. In this study, we found ten point mutations in the gene encoding homeodomain-interacting protein kinase 4 (HIPK4) in patients with NOA, and using in vitro studies, we determined a premature termination point mutation (p. Lys490∗, c.1468A>T) that can cause decreased expression of HIPK4. Our phosphoproteomic analysis of Hipk4^-/- testes revealed phosphorylation of multiple proteins regulated by HIPK4 during spermiogenesis. We also confirmed that a substrate of HIPK4 with four downregulated phosphorylation sites matching the xSPx motif is the known manchette-related protein RIMS-binding protein 3, which is required for sperm head morphogenesis. Therefore, we conclude HIPK4 regulates the phosphorylation of manchette protein RIMS-binding protein 3 and plays essential roles in sperm head shaping and male fertility.

2022-04-01·Drug Development Research3区 · 医学

Receptor interacting protein kinase 4 promotes cell proliferation, migration, and invasion in ovarian cancer via targeting protein kinase C delta

3区 · 医学

Article

作者: Chen, Yinzi ; Zhang, Longhui ; Jin, Aihong ; Fang, Guangguang

AbstractReceptor interacting protein kinase 4 (RIPK4) has been reported to function as an oncogenic role in several types of cancers. The aim of this study was to evaluate the role of RIPK4 in ovarian cancer (OC) cells and to elucidate the mechanism behind this effect. In this study, the GEPIA database was used to analyze the RIPK4 expressions in OC tissues and overall survival. qRT‐PCR and western blot assay were performed to detect the expressions of RIPK4 and protein kinase C delta (PRKCD) in OC cells. In addition, cell proliferation was assessed by CCK‐8 and colony formation assay while cell invasion and migration were evaluated by transwell, wound healing and western blot assay. The interaction of RIPK4 and PRKCD was analyzed by the STRING database and the bioGRID database, and verified with co‐immunoprecipitation. Herein, we describe that RIPK4 expression was upregulated in OC tissues and cells and was associated with poor overall survival. RIPK4 silencing repressed the proliferation, migration, and invasion of OC cells. Mechanistically, PRKCD was highly expressed in OC cells and was combined with RIPK4. PRKCD was highly positively associated with RIPK4 in OC and was regulated by RIPK4. Moreover, PRKCD overexpression reversed the inhibitory effects of RIPK4 silencing on OC cell proliferation, migration, and invasion. RIPK4 functions as an oncogene in OC cells via at least partially binding to PRKCD, which might represent a novel therapeutic strategy for improving survival for patients with OC.

2020-01-01·Bioinformatics3区 · 生物学

Genetic cooperativity in multi-layer networks implicates cell survival and senescence in the striatum of Huntington’s disease mice synchronous to symptoms

3区 · 生物学

Article

作者: Sasidharan Nair, Satish ; Mégret, Lucile ; Aaronson, Jeff ; Verny, Marc ; Neri, Christian ; Fragnaud, Hélissande ; Lejeune, François-Xavier ; Bigan, Erwan ; Rosinski, Jim ; Parmentier, Frédéric

AbstractMotivationHuntington’s disease (HD) may evolve through gene deregulation. However, the impact of gene deregulation on the dynamics of genetic cooperativity in HD remains poorly understood. Here, we built a multi-layer network model of temporal dynamics of genetic cooperativity in the brain of HD knock-in mice (allelic series of Hdh mice). To enhance biological precision and gene prioritization, we integrated three complementary families of source networks, all inferred from the same RNA-seq time series data in Hdh mice, into weighted-edge networks where an edge recapitulates path-length variation across source-networks and age-points.ResultsWeighted edge networks identify two consecutive waves of tight genetic cooperativity enriched in deregulated genes (critical phases), pre-symptomatically in the cortex, implicating neurotransmission, and symptomatically in the striatum, implicating cell survival (e.g. Hipk4) intertwined with cell proliferation (e.g. Scn4b) and cellular senescence (e.g. Cdkn2a products) responses. Top striatal weighted edges are enriched in modulators of defective behavior in invertebrate models of HD pathogenesis, validating their relevance to neuronal dysfunction in vivo. Collectively, these findings reveal highly dynamic temporal features of genetic cooperativity in the brain of Hdh mice where a 2-step logic highlights the importance of cellular maintenance and senescence in the striatum of symptomatic mice, providing highly prioritized targets.Availability and implementationWeighted edge network analysis (WENA) data and source codes for performing spectral decomposition of the signal (SDS) and WENA analysis, both written using Python, are available at http://www.broca.inserm.fr/HD-WENA/.Supplementary informationSupplementary data are available at Bioinformatics online.

项与 HIPK4 相关的新闻（医药）

2024-03-23

·医药观澜

璎黎药业联合开发，创新HIPK2抑制剂在中国获批临床！

▎药明康德内容团队编辑3月22日，璎黎药业宣布其已收到中国国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准该公司开展新型小分子HIPK2变构抑制剂RLA-23174片治疗肾纤维化的临床试验。HIPK是定位于细胞核内的丝氨酸/苏氨酸蛋白激酶，表达于多种组织中，包括大脑、肺、肝、肾、皮肤、肌肉等。HIPK家族有四个直系同源物，称为HIPK1、HIPK2、HIPK3、HIPK4。在HIPK家族中，HIPK2与纤维化关系密切，如心肌结构重建、肝脏纤维化、肺纤维化，肾脏纤维化等，是研究抗纤维化治疗的重要靶点。RLA-23174是璎黎药业和Rila Therapeutics公司合作开发的一种新型小分子HIPK2变构抑制剂。该候选药可通过影响HIPK2和Smad3之间的相互作用来抑制TGF-β/Smad3信号通路，不抑制HIPK2的激酶活性，从而不影响Smad2和p53的磷酸化。由此RLA-23174在发挥抗纤维化作用的同时，还能减少因抑制HIPK2而产生的多种不良反应。临床前研究表明，RLA-23174具有良好的抗纤维化效果、很高的体内外活性、优良的动物体内药代特性和良好的安全性。璎黎药业研发总裁兼上海璎黎总经理许祖盛博士表示：“目前对HIPK2影响肾纤维化的发病机制的认识已取得重要进展，但还没有相应发病机制的新药进入临床研究阶段，临床上非常缺乏针对肾纤维化的有效治疗药物。此次RLA-23174获批临床进入临床研究后，公司将积极推进其临床试验的开展，尽早地为肾纤维化病人提供治疗选择。”参考资料：[1]璎黎药业首个联合开发合作项目-全球新靶点HIPK2抑制剂RLA-23174获得中国临床试验许可. Retrieved Mar 22, 2024. From https://mp.weixin.qq.com/s/WIF_Ml3Y49QDcNgZQ9jVWg本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

申请上市临床1期